Search the Newsreel

Annexon secures USD 200m credit facility to fund late-stage programs through potential commercial launch

Annexon, Inc. has secured a senior secured credit facility of up to $200 million from Oxford Finance LLC. This non-dilutive capital is intended to fund the company's late-stage programs, tanruprubart and vonaprument, through potential commercial launch, avoiding additional equity dilution. The funding is tied …

Annexon, Inc. (NASDAQ:ANNX) Receives Average Recommendation of "Hold" from Analysts

Annexon, Inc. (NASDAQ:ANNX) has received an average "Hold" recommendation from ten analysts, with a 12-month average price target of $15.33 against its recent trading price of $5.07. Insider transactions show significant share purchases by directors William H. Carson and Muneer A. Satter, increasing insider …

BlackRock, Inc. Expands Stake in Annexon Inc (ANNX) with Strategic Share Acquisition

BlackRock, Inc. has significantly increased its stake in Annexon Inc (ANNX) by acquiring over 2.1 million shares, bringing its total holdings to 13.1 million shares, representing an 8% position. This strategic move highlights BlackRock's calculated bet on the long-term potential of the clinical-stage biopharmaceutical …

Annexon secures $200M credit facility with Oxford Finance

Annexon, Inc. (NASDAQ:ANNX) has secured a credit facility worth up to $200 million with Oxford Finance LLC to fund its drug development programs for neuroinflammatory diseases. The biopharmaceutical company received an initial $50 million, with additional funds tied to the achievement of milestones for …

Annexon (Nasdaq: ANNX) obtains up to $200M credit facility from Oxford

Annexon, Inc. secured a credit facility of up to $200 million from Oxford Finance LLC to support its working capital and general business requirements, including advancing its vonaprument and tanruprubart registrational programs. An initial $50 million was funded at closing, with additional tranches tied …

Annexon Secures Up to $200 Million Term Loan Facility With Oxford Finance

Annexon (ANNX) has secured a term loan facility of up to $200 million from Oxford Finance for working capital and general corporate purposes. An initial $50 million was funded at signing, with additional tranches totaling up to $150 million tied to milestones and mutual …

Annexon Inc (ANNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Annexon Inc (ANNX), detailing its performance based on various indicators and moving averages. It presents a summary of technical indicators like MACD, RSI, and CCI, as well as moving average values from MA5 to MA200, highlighting neutral …

Several Annexon Insiders Sell Shares Sending Potential Negative Signal

The article reports that several Annexon insiders have sold shares, potentially signaling a negative outlook for the company. This move often raises concerns among investors regarding the company's future performance.

Exosens : CA +15,3% au T1, résultats annuels attendus dans le haut des prévisions

EXOZ|eXoZymes Inc|Price:4.500|Chg%:-0.210

eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme company that transforms sustainable feedstock into essential chemicals, medicines, and biofuels. The company uses AI to create advanced enzymes that operate in bioreactors, offering a sustainable alternative to traditional chemical production. …

Annexon Inc (ANNX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Annexon Inc (ANNX), focusing on its profitability and balance sheet. It notes the company's current stock price, market capitalization, and indicates that a detailed financial analysis is available within the "Financials" section of the TradingKey platform. …

ANNX|Annexon Inc|Price:5.130|Chg%:-0.090

This article provides a detailed company profile for Annexon Inc (ANNX), a clinical-stage biopharmaceutical company focusing on novel therapies for neuroinflammatory diseases. It outlines their business scope, lead product candidates (ANX005, ANX1502, ANX007), key financial data points such as market capitalization, and lists company …

Annexon Inc (ANNX) Cash Flow

This article provides a detailed cash flow statement for Annexon Inc (ANNX), presenting both quarterly and annual data for operating, investing, and financing activities. It includes key figures like operating cash flow, capital expenditures, net income, and free cash flow, along with year-over-year percentage …

ANNX|Annexon Inc|Price:5.325|Chg%:-0.065

This article provides a detailed company profile for Annexon Inc (ANNX), a clinical-stage biopharmaceutical company focusing on novel therapies for neuroinflammatory diseases. It outlines their business scope, lead product candidates (ANX005, ANX1502, ANX007), key financial data points such as market capitalization, and lists company …

Annexon Inc (ANNX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Annexon Inc (ANNX), focusing on volatility, financial risk, and investment risk. It details various metrics such as Beta vs S&P 500 index, VaR, maximum drawdown, realized volatility, and liquidity indicators like average turnover rate. The data presented …

eXoZymes Inc. Revenue Breakdown – NASDAQ:EXOZ

Annexon Inc (ANNX) Institutional Confidence

This article from TradingKey provides an overview of Annexon Inc.'s (ANNX) institutional confidence, detailing the shareholdings and recent activity of major institutional investors. Firms like Redmile Group, Alerce Investment Management, and BVF Partners L.P. hold significant stakes and have shown varying degrees of change …

Annexon Inc (ANNX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Annexon Inc (ANNX), listing its major shareholders and institutional holdings. It provides updated information on the proportion held by various investment entities, shareholder types, and historical institutional shareholding data. The article also lists Annexon's presence in several …

Annexon Inc (ANNX) Income Statement

Annexon (ANNX) Short Interest & Short Float | Updated Jul 2026

Annexon (ANNX) had a short interest of 29.83 million shares as of July 15, 2026, representing 20.30% of its public float, an increase of 0.75% from the previous report. The short interest ratio is 5.7 days to cover, indicating it would take approximately 5.7 …

TradingKey

This article provides a detailed quarterly balance sheet for Annexon Inc. (ANNX), including data on cash, short-term investments, receivables, prepaid expenses, various asset categories, and liabilities. It also offers FAQs about important balance sheet metrics, the difference between assets, liabilities, and shareholders' equity, and …

Annexon Inc (ANNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Annexon Inc (ANNX), detailing analyst ratings and price targets. Based on 12 analysts, the stock has a "Buy" consensus with a target price indicating a potential 170.44% upside. The article also includes information on past and future …

Annexon Price Target Announced at $3.00/Share by Citizens

Citizens has announced a price target of $3.00 per share for Annexon. This update reflects the firm's latest valuation of the company's stock. Investors and market watchers will likely consider this target in their assessment of Annexon's potential performance.

Citizens initiates Annexon stock with underperform on GA trial concerns By Investing.com

Citizens has initiated coverage on Annexon Biosciences (NASDAQ:ANNX) with a Market Underperform rating and a $3.00 price target, citing concerns that Annexon's Phase 3 geographic atrophy trial for vonaprument may not replicate Phase 2 vision benefits. This bearish outlook contrasts with the more optimistic …

H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14

H.C. Wainwright has reiterated its Buy rating on Annexon (ANNX.US) and maintained its target price at $14. This indicates continued confidence from the firm in Annexon's stock performance and future prospects.

Weekly Recap: ARCHER II enrollment completed and 335K options to two hires

Annexon, Inc. (NASDAQ:ANNX) has completed enrollment for its Phase 3 ARCHER II trial for vonaprument, with topline results anticipated in Q4 2026. The company also disclosed that it granted 335,000 inducement options to two new non-executive hires in July 2026. Details on Phase 2 …

H.C. Wainwright reiterates Buy on Annexon stock, $14 target By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $14.00 price target for Annexon Biosciences (NASDAQ:ANNX) following baseline analyses from ARCHER data. The firm highlighted data from the ARCHER study showing 15-letter loss events clustered within a specific BCVA range and noted that the …

Two New Annexon Employees Receive 10-Year Options at $6.50

Annexon (Nasdaq: ANNX) has granted stock options for an aggregate of 335,000 common shares to two new non-executive employees under its 2022 Employment Inducement Award Plan. The options have a ten-year term with an exercise price of $6.50 per share, which was the closing …

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to two new non-executive employees under the terms of its 2022 Employment Inducement Award Plan. These equity awards, approved on July 12, 2026, consist of options to purchase 335,000 shares of common stock with an exercise price …

Needham raises Annexon Biosciences stock price target to $25 on trial

Needham has increased its price target for Annexon Biosciences (NASDAQ:ANNX) to $25 from $11, reiterating a Buy rating, citing the significant upside potential from the current trading price of $5.55. The firm anticipates a positive outcome from the pivotal Phase 3 ARCHER II trial …

Annexon (ANNX) filer Thomas Wiggans eyes 2,000-share NASDAQ stock sale

Thomas Wiggans, a shareholder in Annexon (ANNX), has filed a notice for the proposed sale of 2,000 common shares via Fidelity Brokerage Services LLC on NASDAQ, with an indicated value of $12,630.01. This planned sale follows a previous sale of 1,000 common shares by …

ANNX Maintained by Needham -- Price Target Raised to $25

Needham analyst Joseph Stringer maintained a 'Buy' rating on Annexon (ANNX) and significantly raised the price target from $11.00 to $25.00, reflecting strong confidence in the company's growth potential. Despite a low GF Score of 34/100, primarily due to profitability challenges, the company shows …

Annexon to present data on vonaprument for macular degeneration By Investing.com

Annexon Inc. is set to present Phase 2 ARCHER trial data on its drug candidate, vonaprument, for geographic atrophy at the American Society of Retina Specialists 44th Annual Scientific Meeting. This data will inform patient selection for the ongoing Phase 3 ARCHER II trial, …

Flexopack Societe Anonyme Commercial and Industrial Plastics : ANNOUNCEMENT OF REGULATED INFORMATION - TRANSACTIONS NOTIFICATION

Sodexo bondit de près de 10 % après ses résultats : redressement ou emballement ?

Sodexo: Prévisions et Estimations des Analystes | SW